| Visible light photocatalysis in the late-stage functionalization of pharmaceutically relevant compounds R Cannalire, S Pelliccia, L Sancineto, E Novellino, GC Tron, ... Chemical Society Reviews 50 (2), 766-897, 2021 | 256 | 2021 |
| Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities R Cannalire, C Cerchia, AR Beccari, FS Di Leva, V Summa Journal of medicinal chemistry 65 (4), 2716-2746, 2020 | 184 | 2020 |
| Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen M Kuzikov, E Costanzi, J Reinshagen, F Esposito, L Vangeel, M Wolf, ... ACS pharmacology & translational science 4 (3), 1096-1110, 2021 | 117 | 2021 |
| SARS-CoV-2 entry inhibitors: Small molecules and peptides targeting virus or host cells R Cannalire, I Stefanelli, C Cerchia, AR Beccari, S Pelliccia, V Summa International journal of molecular sciences 21 (16), 5707, 2020 | 77 | 2020 |
| Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor D Tarantino, R Cannalire, E Mastrangelo, R Croci, G Querat, ML Barreca, ... Antiviral research 134, 226-235, 2016 | 58 | 2016 |
| A journey around the medicinal chemistry of hepatitis C virus inhibitors targeting NS4B: from target to preclinical drug candidates R Cannalire, ML Barreca, G Manfroni, V Cecchetti Journal of medicinal chemistry 59 (1), 16-41, 2016 | 56 | 2016 |
| The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors G Manfroni, R Cannalire, ML Barreca, N Kaushik-Basu, P Leyssen, ... Journal of medicinal chemistry 57 (5), 1952-1963, 2014 | 52 | 2014 |
| Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities A Corona, K Wycisk, C Talarico, C Manelfi, J Milia, R Cannalire, ... ACS pharmacology & translational science 5 (4), 226-239, 2022 | 50 | 2022 |
| 2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction T Felicetti, R Cannalire, D Pietrella, G Latacz, A Lubelska, G Manfroni, ... Journal of medicinal chemistry 61 (17), 7827-7848, 2018 | 49 | 2018 |
| Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against Escherichia coli D Machado, L Fernandes, SS Costa, R Cannalire, G Manfroni, O Tabarrini, ... PeerJ 5, e3168, 2017 | 38 | 2017 |
| New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors G Manfroni, D Manvar, ML Barreca, N Kaushik-Basu, P Leyssen, ... Journal of medicinal chemistry 57 (8), 3247-3262, 2014 | 37 | 2014 |
| Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3‐Phenyl‐1,4‐benzothiazine Analogues T Felicetti, R Cannalire, MS Burali, S Massari, G Manfroni, ML Barreca, ... ChemMedChem 12 (16), 1293-1302, 2017 | 35 | 2017 |
| Functionalized 2, 1-benzothiazine 2, 2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase R Cannalire, D Tarantino, A Astolfi, ML Barreca, S Sabatini, S Massari, ... European journal of medicinal chemistry 143, 1667-1676, 2018 | 32 | 2018 |
| Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium R Cannalire, D Machado, T Felicetti, SS Costa, S Massari, G Manfroni, ... European Journal of Medicinal Chemistry 140, 321-330, 2017 | 32 | 2017 |
| Pyridobenzothiazolones exert potent anti-dengue activity by hampering multiple functions of NS5 polymerase R Cannalire, KW Ki Chan, MS Burali, CP Gwee, S Wang, A Astolfi, ... ACS Medicinal Chemistry Letters 11 (5), 773-782, 2020 | 27 | 2020 |
| Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium D Machado, R Cannalire, S Santos Costa, G Manfroni, O Tabarrini, ... ACS Infectious Diseases 1 (12), 593-603, 2015 | 25 | 2015 |
| Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions R Cannalire, D Tarantino, G Piorkowski, T Carletti, S Massari, T Felicetti, ... Antiviral Research 167, 6-12, 2019 | 24 | 2019 |
| Broad‐spectrum flavivirus inhibitors: a medicinal chemistry point of view T Felicetti, G Manfroni, V Cecchetti, R Cannalire ChemMedChem 15 (24), 2391-2419, 2020 | 22 | 2020 |
| Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position T Felicetti, R Cannalire, MG Nizi, O Tabarrini, S Massari, ML Barreca, ... European Journal of Medicinal Chemistry 155, 428-433, 2018 | 21 | 2018 |
| Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation A Astolfi, M Kudolo, J Brea, G Manni, G Manfroni, D Palazzotti, S Sabatini, ... European Journal of Medicinal Chemistry 182, 111624, 2019 | 20 | 2019 |
